ING Groep NV significantly increased its investment in healthcare giant Johnson & Johnson (JNJ) during the third quarter, acquiring an additional 266,299 shares. This strategic move brings ING's total holdings in JNJ to 959,228 shares, valued at an impressive $177.86 million. The increased stake signals strong institutional confidence in Johnson & Johnson's market position and future prospects. Analysts currently maintain a "Moderate Buy" consensus rating for JNJ, with a target price set at $233.73, further reinforcing positive sentiment. Moreover, Johnson & Johnson recently declared a quarterly dividend of $1.30 per share, payable on March 10th. This substantial institutional investment, combined with positive analyst outlooks and consistent dividend payouts, underscores a bullish sentiment surrounding JNJ stock.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis